Xuan Pei

459 total citations
17 papers, 311 citations indexed

About

Xuan Pei is a scholar working on Molecular Biology, Oncology and Reproductive Medicine. According to data from OpenAlex, Xuan Pei has authored 17 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 8 papers in Oncology and 7 papers in Reproductive Medicine. Recurrent topics in Xuan Pei's work include Ovarian cancer diagnosis and treatment (7 papers), Genetic factors in colorectal cancer (3 papers) and Chromatin Remodeling and Cancer (3 papers). Xuan Pei is often cited by papers focused on Ovarian cancer diagnosis and treatment (7 papers), Genetic factors in colorectal cancer (3 papers) and Chromatin Remodeling and Cancer (3 papers). Xuan Pei collaborates with scholars based in China, India and Germany. Xuan Pei's co-authors include Huijuan Yang, Libing Xiang, Wei Jiang, Shuang Ye, Xuxia Shen, Ziliang Wang, Yingying Zheng, Shuai Liu, Shyamal Goswami and Xiaohua Wu and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Molecular Sciences and International Journal of Cancer.

In The Last Decade

Xuan Pei

15 papers receiving 309 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xuan Pei China	8	142	120	102	81	44	17	311
Víctor Rodríguez-Freixinós Spain	11	194 1.4×	84 0.7×	61 0.6×	60 0.7×	23 0.5×	27	319
Sayaka Ueno Japan	10	85 0.6×	85 0.7×	32 0.3×	39 0.5×	95 2.2×	29	309
Domenico Ferraioli France	10	135 1.0×	117 1.0×	30 0.3×	43 0.5×	80 1.8×	27	314
Areeg Faggad Sudan	12	96 0.7×	268 2.2×	33 0.3×	164 2.0×	21 0.5×	18	406
Tong Shu China	8	87 0.6×	174 1.4×	37 0.4×	49 0.6×	29 0.7×	22	251
Rebecca Waters United States	8	103 0.7×	78 0.7×	40 0.4×	45 0.6×	9 0.2×	35	251
Cunxian Zhang United States	11	71 0.5×	60 0.5×	61 0.6×	63 0.8×	138 3.1×	30	347
Anni Innamaa United Kingdom	5	209 1.5×	89 0.7×	49 0.5×	79 1.0×	33 0.8×	13	343
Shuqi Chi China	11	56 0.4×	191 1.6×	18 0.2×	101 1.2×	88 2.0×	19	346
Zuyang Yuan China	9	49 0.3×	81 0.7×	53 0.5×	38 0.5×	7 0.2×	13	192

Countries citing papers authored by Xuan Pei

Since Specialization

Citations

This map shows the geographic impact of Xuan Pei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xuan Pei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xuan Pei more than expected).

Fields of papers citing papers by Xuan Pei

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xuan Pei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xuan Pei. The network helps show where Xuan Pei may publish in the future.

Co-authorship network of co-authors of Xuan Pei

This figure shows the co-authorship network connecting the top 25 collaborators of Xuan Pei. A scholar is included among the top collaborators of Xuan Pei based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xuan Pei. Xuan Pei is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

Ye, Shuang, Yi Fu, Jun Wang, et al.. (2025). Surufatinib Combined With Toripalimab For The Treatment Of Recurrent Ovarian Clear Cell Carcinoma: Update Of A Prospective Single Center, Single-Arm Phase II Clinical Trial. International Journal of Gynecological Cancer. 35(2). 101019–101019.

Zwingenberger, Stefan, et al.. (2025). Early Night-Time Bracing for Mild Adolescent Idiopathic Scoliosis: A Retrospective Cohort Study. Global Spine Journal. 3054325966–3054325966.

Yang, Huijuan, Wei Jiang, Xuan Pei, et al.. (2025). Efficacy and safety of distamab vedotin combined with carboplatin and bevacizumab for HER2-expressing platinum-sensitive ovarian cancer with prior PARPi treatment.. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations

Fu, Yi, Xuan Pei, Shuang Ye, et al.. (2024). Efficacy and safety of nanoparticle albumin-bound paclitaxel plus carboplatin as neoadjuvant chemotherapy for stages III–IV, unresectable ovarian cancer: a single-arm, open-label, phase Ib/II study. BMC Medicine. 22(1). 496–496. 3 indexed citations

Jiang, Wei, Chunjuan Jiang, Qianlan Yao, et al.. (2023). A NOTCH1 Mutation Found in a Newly Established Ovarian Cancer Cell Line (FDOVL) Promotes Lymph Node Metastasis in Ovarian Cancer. International Journal of Molecular Sciences. 24(6). 5091–5091. 4 indexed citations

Ye, Shuang, Shuling Zhou, Yutuan Wu, et al.. (2023). Genomic profiling of ovarian clear cell carcinoma in Chinese patients reveals potential prognostic biomarkers for survival. Annals of Medicine. 55(1). 2218104–2218104. 3 indexed citations

Pei, Xuan, Mingzhu Lei, Haojie Lu, et al.. (2022). Palmitoylation of MDH2 by ZDHHC18 activates mitochondrial respiration and accelerates ovarian cancer growth. Science China Life Sciences. 65(10). 2017–2030. 47 indexed citations

Pei, Xuan, Libing Xiang, Wei Chen, et al.. (2021). The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix. Gynecologic Oncology. 161(3). 779–786. 31 indexed citations

Chen, Wei, Shuang Ye, Yutuan Wu, et al.. (2021). Changes in peripheral lymphocyte populations in patients with advanced/recurrent ovarian cancer undergoing splenectomy during cytoreductive surgery. Journal of Ovarian Research. 14(1). 113–113. 1 indexed citations

10.

Wu, Yutuan, Shuang Ye, Shyamal Goswami, et al.. (2020). Clinical significance of peripheral blood and tumor tissue lymphocyte subsets in cervical cancer patients. BMC Cancer. 20(1). 173–173. 37 indexed citations

11.

Yang, Huijuan, Shuang Ye, Shyamal Goswami, et al.. (2019). Highly immunosuppressive HLADR^hi regulatory T cells are associated with unfavorable outcomes in cervical squamous cell carcinoma. International Journal of Cancer. 146(7). 1993–2006. 20 indexed citations

12.

Jiang, Wei, Shuai Liu, Yingying Zheng, et al.. (2018). The PIK3CA E542K and E545K mutations promote glycolysis and proliferation via induction of the β-catenin/SIRT3 signaling pathway in cervical cancer. Journal of Hematology & Oncology. 11(1). 139–139. 71 indexed citations

13.

Jiang, Wei, Shuang Ye, Libing Xiang, et al.. (2018). Establishment and molecular characterization of a human ovarian clear cell carcinoma cell line (FDOV1). Journal of Ovarian Research. 11(1). 58–58. 4 indexed citations

14.

Jiang, Wei, Libing Xiang, Xuan Pei, et al.. (2017). Mutational analysis of KRAS and its clinical implications in cervical cancer patients. Journal of Gynecologic Oncology. 29. 3 indexed citations

15.

Pei, Xuan, Libing Xiang, Shuang Ye, et al.. (2017). Cycles of cisplatin and etoposide affect treatment outcomes in patients with FIGO stage I-II small cell neuroendocrine carcinoma of the cervix. Gynecologic Oncology. 147(3). 589–596. 28 indexed citations

16.

Xiang, Libing, Wei Jiang, Shuang Ye, et al.. (2017). ERBB2 mutation: A promising target in non-squamous cervical cancer. Gynecologic Oncology. 148(2). 311–316. 29 indexed citations

17.

Jiang, Wei, Libing Xiang, Xuan Pei, et al.. (2017). Mutational analysis ofKRASand its clinical implications in cervical cancer patients. Journal of Gynecologic Oncology. 29(1). e4–e4. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact